Please login to the form below

Not currently logged in
Email:
Password:

First application for FDA/EMA review pilot

Pfizer has submitted the first application for the European Medicines Agency's and the US Food and Drug Administration's 'quality by design' pilot for increased co-operation in drug evaluations

Pfizer has submitted the first application for the European Medicines Agency's (EMA) and the US Food and Drug Administration's (FDA) 'quality by design' pilot for increased co-operation in drug evaluations.

The voluntary pilot programme was announced in March 2011 to help ensure consistent implementation of certain guidelines from regulatory agencies when reviewing marketing applications for new drugs.

The programme is designed to encourage regular communication and consultation between the EMA and FDA during the assessment of the design and development of formulations and manufacturing processes listed in the application. This is to help ensure product manufacturing quality.

The pilot is being operated under the EMA's confidentiality arrangements with the FDA, covering issues related to medicinal products for human and veterinary use. In September 2010, the agencies said they would indefinitely extend these arrangements.

20th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics